Altium Capital Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Altium Capital Management’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-40,000	Closed	-$2.02M	–	81
2024 Q3	$2.02M	Sell	40,000 -75,000	-65%	-$3.51M	0.59%	42
2024 Q2	$5.06M	Buy	+115,000	New	+$4.87M	2.06%	19
2023 Q4	–	Sell	-88,000	Closed	-$5.02M	–	81
2023 Q3	$5.02M	Hold	88,000	–	–	2.62%	15
2023 Q2	$4.49M	Buy	+88,000	New	+$2.37M	3.4%	10
2022 Q1	–	Sell	-250,000	Closed	-$2.47M	–	144
2021 Q4	$2.47M	Hold	250,000	–	–	0.68%	58
2021 Q3	$2.49M	Hold	250,000	–	–	0.65%	63
2021 Q2	$2.59M	Hold	250,000	–	–	0.6%	67
2021 Q1	$2.55M	Hold	250,000	–	–	0.71%	59
2020 Q4	$2.84M	Buy	+250,000	New	+$2.65M	1.06%	41

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Altium Capital Management's MLTX Position: Q4 2024 in Review

Altium Capital Management sold out of MoonLake Immunotherapeutics (MLTX) in Q4 2024, closing a stake of 40,000 shares — an estimated $2.02M sold.

Altium Capital Management first reported a position in MLTX in Q4 2020 and held it in 9 quarters. The position peaked at $5.06M in Q2 2024. 115 funds tracked by Wall St. Rank hold MLTX as of Q4 2024.

Altium Capital Management reported no remaining MoonLake Immunotherapeutics position as of Q4 2024 after selling out during the quarter.
Altium Capital Management sold 40,000 MoonLake Immunotherapeutics shares in Q4 2024, an estimated $2.02M.
Altium Capital Management first reported a position in MoonLake Immunotherapeutics in Q4 2020 and held it in 9 quarters.
Altium Capital Management's MoonLake Immunotherapeutics position peaked at $5.06M in Q2 2024.
115 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q4 2024.

Based on Altium Capital Management's 13F filing for Q4 2024, filed 13 Feb 2025.